Good morning, everyone, and welcome to another working week. We hope the weekend was refreshing and relaxing, because that demanding routine of deadlines and meetings has returned. You knew this was inevitable, yes? Well, to cope, perhaps you would like to join us for a cup of stimulation to fortify those nerve endings. We are opting for golden French toast, by the way. So time to get started. Here are some items of interest. Hope your day goes well and do stay in touch …

Esperion Therapeutics (ESPR) reported that a combination of its once-a-day cholesterol pill and a maximum dose of a statin lowered LDL cholesterol 18 percent more than statins alone after 12 weeks, STAT reports. The results come from the last of five successful trials on the drug, called bempedoic acid, whose data the company plans to submit to the Food and Drug Administration in the early months of 2019. To cardiologists, the most important finding related to safety. In the 779-patient study, the drug was indistinguishable from placebo when it came to side effects and deaths.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy